Apogee Therapeutics, Inc. APGE Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities?
- Apogee Therapeutics, Inc. (APGE) reported accrued expenses and other current liabilities of $28.58M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities increased by 7.7% year-over-year, from $26.54M to $28.58M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s accrued expenses and other current liabilities has grown at a 15.7% compound annual growth rate (CAGR), from $17.31M to $23.18M.
- What does accrued expenses and other current liabilities mean?
- This metric represents the aggregate of short-term obligations that have been incurred but not yet invoiced or paid by the end of the reporting period. It typically includes items such as accrued compensation, professional fees, and other operational costs essential to the company's research and development activities. Monitoring this balance provides insight into the company's near-term cash outflow requirements and the timing of its operational spending.